Видео ютуба по тегу Mcrpc

Perspectives in mCRPC in 2024
Perspectives in mCRPC in 2024
ADT Resistant Metastatic Prostate Cancer (mCRPC) - 2021 Prostate Cancer Patient Conference
ADT Resistant Metastatic Prostate Cancer (mCRPC) - 2021 Prostate Cancer Patient Conference
UROwebinar: New treatment options in mCRPC
UROwebinar: New treatment options in mCRPC
Overall Survival Data in mCRPC
Overall Survival Data in mCRPC
Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
PARPi in mCRPC
PARPi in mCRPC
Management of mCRPC in China
Management of mCRPC in China
Potential role of rituximab in mCRPC
Potential role of rituximab in mCRPC
MCRPC Transportation Technical Committee Meeting 4/17/25
MCRPC Transportation Technical Committee Meeting 4/17/25
The Differences Between mCRPC and nmCRPC
The Differences Between mCRPC and nmCRPC
Ep. 10: How Has the mCRPC Treatment Landscape Changed?
Ep. 10: How Has the mCRPC Treatment Landscape Changed?
Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
Point-Counterpoint: Management of mCRPC
Point-Counterpoint: Management of mCRPC
Metastatic Castration Resistant Prostate Cancer (mCRPC) – Inroads in Improved Outcomes
Metastatic Castration Resistant Prostate Cancer (mCRPC) – Inroads in Improved Outcomes
Phase 1 Trial of ARV-110 in Patients with mCRPC
Phase 1 Trial of ARV-110 in Patients with mCRPC
Risk-Adapted Treatment Monitoring in mCRPC APCCC 2022
Risk-Adapted Treatment Monitoring in mCRPC APCCC 2022
mCRPC Lu-177 PSMA and Beyond with Dr. William K. Oh
mCRPC Lu-177 PSMA and Beyond with Dr. William K. Oh
M2 - Evolving landscape of PARP inhibitors in mCRPC: combination with anti-androgens
M2 - Evolving landscape of PARP inhibitors in mCRPC: combination with anti-androgens
Molecular and clinical characterization of mCRPC patients achieving deep PSA responses to BAT
Molecular and clinical characterization of mCRPC patients achieving deep PSA responses to BAT